Phytic Acid Dosage for Reducing Amyloid Beta Aggregation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for Alzheimer's Disease, particularly those involving scyllo inositol, require high doses that are burdensome and may cause side effects, while existing phytic acid treatments are not effective at reducing beta amyloid protein aggregation in the brain.

Innovation Solution

Administration of low doses of phytic acid, phytate salts, or their isomers/hydrolysates, ranging from 0.5 to 18.75 grams per day, which are more effective than scyllo inositol and myo inositol in preventing and treating Alzheimer's Disease by reducing beta amyloid protein aggregation, and can be administered orally or topically.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If high doses of scyllo inositol are administered to treat Alzheimer's Disease, then therapeutic effect is improved, but patient burden and side effects increase

Engineering Contradiction:

Improvetherapeutic effectVSAvoidpatient burden

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent changes the chemical parameter from scyllo inositol to phytic acid and its derivatives, which allows achieving the same therapeutic effect at much lower doses (0.5-18.75 grams per day versus higher doses of scyllo inositol), thereby reducing patient burden while maintaining efficacy

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs phytic acid and its derivatives which are naturally occurring, cost-effective compounds derived from plant seeds, replacing more expensive synthetic alternatives while maintaining therapeutic effectiveness at lower doses

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

2Ease of operation

If phytic acid is administered to treat Alzheimer's Disease, then treatment convenience is improved, but effectiveness in reducing beta amyloid protein aggregation is insufficient

Engineering Contradiction:

Improvetreatment convenienceVSAvoideffectiveness

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent uses composite approaches by combining phytic acid with specific enzymes (phytases) or metal ions (zinc, calcium, magnesium) to create phytate salts and hydrolysates that enhance the effectiveness of phytic acid in reducing beta amyloid protein aggregation while maintaining treatment convenience

Inventive Principle:

Principle #40Composite materials

Solution Approach 2:

The patent modifies the chemical structure parameters of phytic acid by creating derivatives with different phosphate group configurations (phytate salts with varying degrees of dephosphorylation) to optimize both effectiveness in reducing amyloid aggregation and treatment convenience

Inventive Principle:

Principle #35Parameter changes

3Reliability

If phytic acid and its derivatives are used to reduce beta amyloid protein aggregation, then therapeutic effectiveness is improved, but dosage precision requirements increase

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoiddosage precision

Core Design Contradiction:

ReliabilityVSManufacturing precision

Solution Approach 1:

The patent establishes a broad effective dosage range (0.5-18.75 grams per day) by adjusting chemical parameters such as the degree of phytic acid hydrolysis and metal ion composition in phytate salts, allowing flexible dosing while maintaining therapeutic effectiveness and reducing precision requirements

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS11510932B2Prophylactic and therapeutic treatment of alzheimer's disease using phytic acid and phytate to reduce amyloid beta plaque and tau protein

Publication Date: 2022.11.29 SABIN ROBERT

AI summary

A composition and method for the treatment of Alzheimer's disease and related amyloid plaque development and reduction of amyloid plaque, amyloidosis and amyotrophic lateral sclerosis, includes an effective amount of a compound selected from the group consisting of phytic acid, a phytate salt, an isomer or hydrolysate of phytic acid or a phytate salt, or a mixture of any combination thereof, being administered to a person in an amount from about 0.5 grams to about 18.75 grams per day.